GE Healthcare reacts to the number of regenerative medicine companies operating globally by announcing plans for a facility to create single-use kits and advanced therapies.
BeiGene’s immunotherapy becomes its first treatment to receive approval in China and Boehringer announces that it has begun manufacture of the product.
GE Healthcare tops its C-Pro cell processing system with SpinOculation, an automation software that enables closed T cells transduction at the preferred volume and concentration.
GE Healthcare assigns Pharmadule Morimatsu to expand the offering of its ‘factory in a box’, known as KUBio, enabling the scale-up of biologics manufacture.
GE to set up its FlexFactory platform for antibody manufacturing at Akeso’s facility in Guangzhou, aiming to optimize the latter’s biologics production.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.
GE Healthcare teams up with Germfree to create a fully integrated, expandable manufacturing solution that is geared towards the development of ‘emerging biotherapeutics’.
The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.
‘We don’t want to change the way we work,’ says GE Healthcare Life Sciences CEO, as Danaher’s $21bn acquisition of the BioPharma business continues in the background.
GE Healthcare partners with Rockwell to improve bioprocessing automation operations, which could reduce review time of batch files and processes by weeks.
GE Healthcare partners for digital data exchange collaboration program with Amgen to advance understanding of biomanufacturing process on raw material variability.
The rapid evolution of cell and gene therapy technology is leading GE Healthcare to explore partnerships to meet increasing manufacturing demand, according to the company's enterprise solutions leader.
GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.
The explosion of the gene therapy industry is leading to supply issues, which has led one company to view producing its own clinical materials as its best option.
GE Healthcare and G-CON have combined capabilities to offer drug developers ‘readily deployable’ manufacturing platforms for cell therapies and viral vectors.
The second phase of Changzhou Qianhong Bio-pharma manufacturing project sees a further ¥1 billion devoted to increasing tablet and injection production.
Biopharma-Reporter takes you inside the recently opened Testa BioProcess Innovation Center in Uppsala, Sweden, and speaks with CEO of GE Nordics, Lotta Ljungqvist.
The Testa BioProcess Innovation Center in Sweden will help academics, startups, and biopharmaceutical companies secure industrial proof-of-concepts quicker, and with less cost, says GE Healthcare.
Cellular Biomedicine Group Inc (CBMG) has selected GE Healthcare’s FlexFactory technology for its CAR-T therapy production facility in Shanghai, China.
Cell therapy firms will be able to authenticate the foetal bovie serum (FBS) they use through a testing programme launched by GE Healthcare and Oritain.
Dr Reddy’s will expand its biosimilar manufacturing capacity in Hyderabad by 4,000L using GE Healthcare’s FlexFactory platform based on single-use technologies.
United BioPharma Inc. (UBP), with government backing, has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan.
There is a growing trend among vendors to integrate automation technologies into their offerings says a bioprocessing expert, as GE Healthcare invests in its partner Zenith.
GE Healthcare has acquired cryopreservation technology firm Asymptote and says more investments are likely as it builds an “end-to-end ecosystem” for cellular therapy production services.
Arven will use GE Healthcare’s FlexFactory manufacturing platform to increase capacity at its mammalian-cell based bioproduction facility in Kirklareli, Turkey.
Jacobs Engineering Group has been contracted to collaborate with GE Healthcare on the development of Pfizer’s $350m monoclonal antibody manufacturing centre in Hangzhou, China.
Welsh chromatography resin maker Purolite says it aims to capture 30% of the Protein A market through its 100,000L facility on track to open next year.
Single-use technology is driving a new era in vaccine development says PnuVax which has acquired IP from GE Healthcare to produce an inactivated yellow fever vaccine.
Industry’s uptake of stainless steel systems continues to fall as biomanufacturers move away from large volume blockbuster biologics, according to GE Healthcare.
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.
Turkey’s efforts to increase local biopharmaceutical production have prompted GE Healthcare Life Sciences to set up a biopharmaceutical technology training centre in Istanbul.
GE Healthcare Life Sciences has signed a licensing agreement for Promosome’s suite of mammalian cell line development technologies, which aim to increase protein expression in mammalian cell culture.
US defence contractor Nanotherapeutics will use a modular biomanufacturing system provided by GE Healthcare at a facility it is building in Alachua, Florida.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
Two products aimed at enhancing the efficiency of process
development in biopharmaceutical manufacturing are the latest
offerings from GE Healthcare, the UK-based medical technology and
services company.
GE Healthcare has recently launched a number of diverse and
transformational medical technologies aimed at improving
productivity across the pharmaceutical manufacturing sector.
